论文部分内容阅读
目的观察应用复方铝酸铋胶囊联合兰索拉唑治疗反流性食管炎(RE)的疗效。方法 90例RE患者随机分成3组,每组30例。A组给予兰索拉唑及复方铝酸铋胶囊,B组给予兰索拉唑,C组给予复方铝酸铋胶囊。3组疗程均4周。疗程结束后进行临床疗效评价并复查胃镜。结果 4周后RE愈合率A组达86.7%,B组达73.3%,C组达56.7%;3组症状缓解率分别为90.0%、76.7%和56.7%;A组RE愈合率及症状缓解率均明显高于于C组(P均<0.01),也较B组有所增高,但差异无统计学意义(P均>0.05)。结论兰索拉唑联合复方铝酸铋胶囊治疗RE的疗效明显优于单用复方铝酸铋胶囊,且有优于单药兰索拉唑的趋势。
Objective To observe the curative effect of compound bismuth aluminate and lansoprazole on reflux esophagitis (RE). Methods 90 cases of RE patients were randomly divided into 3 groups, 30 cases in each group. Group A was given lansoprazole and compound bismuth aluminate capsule, group B was given lansoprazole, and group C was given compound bismuth aluminate capsule. The three groups were treated for 4 weeks. After the end of the course of clinical efficacy evaluation and review gastroscopy. Results After 4 weeks, the healing rate of RE was 86.7% in group A, 73.3% in group B and 56.7% in group C, and the symptom relief rate was 90.0%, 76.7% and 56.7% in group A respectively. The healing rate and symptom relief rate Were significantly higher than those in group C (all P <0.01) and also higher than those in group B, but the difference was not statistically significant (all P> 0.05). Conclusions The efficacy of lansoprazole combined with compound bismuth aluminate capsule in the treatment of RE is obviously better than that of compound bismuth aluminate alone, which is superior to that of single-drug lansoprazole.